Tekturna's future looks dim as Novartis cuts 1,960 jobs
This article was originally published in Scrip
Executive Summary
The future of Novartis's antihypertensive Tekturna/Rasilez (aliskiren) is looking increasingly bleak after the company announced today that it would accelerate planned sales force job cuts because of the recent failure of a major trial of the product. The Swiss firm is to cut its US field force by 1,630 positions and reduce staff at headquarters in New Jersey by 330 positions.